证券代码：300181 证券简称：佐力药业 公告编号：2023-041 浙江佐力药业股份有限公司 关于控股子公司参与上海市中成药带量采购拟中选的 公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，浙江佐力药业股份有限公司（以下简称"公司"）控股子公司青海珠 峰冬虫夏草药业有限公司（以下简称"珠峰药业"）参加了上海市中成药带量采 购的投标工作，根据上海阳光医药采购网于 2023 年 8 月 28 日发布的《上海市中 成药带量采购拟中选结果公示》（沪药事药品〔2023）87 号〕显示，公司控股子 公司珠峰药业产品百令片拟中选本次带量采购，现将相关情况公告如下： 注：上述品种的拟中选价格以上海阳光医药采购网发布的最终数据为准。根据上海阳光 医药采购网于 2023 年 8 月 15 日发布的《关于开展本市中成药带量采购有关工作的通知》 （沪药事药品〔2023）84 号〕的规定："采购周期为两年，视情况可延长。采购周期内采购 协议每年一签，续签采购协议时，约定采购量原则上不少于上一年。采购周期内医疗机构应 优先使用本次药品集中采购中选药品，并确保完成约定采购 ...

本次变更保荐代表人后，公司 2022 年度向特定对象发行股票的保荐代表人 为崔敏捷女士和黄世瑾先生，持续督导期至 2024 年 12 月 31 日止。公司董事会 对持续督导保荐代表人刘源先生和刘伟石先生在公司持续督导期所做出的努力 表示衷心感谢！ 特此公告。 浙江佐力药业股份有限公司 证券代码：300181 证券简称：佐力药业 公告编号：2023-040 浙江佐力药业股份有限公司 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于近日收到保荐机构国金 证券股份有限公司（以下简称"国金证券"）出具的《关于更换浙江佐力药业股 份有限公司持续督导保荐代表人的函》，国金证券为公司 2022 年度向特定对象 发行股票的保荐机构，原委派刘源先生和刘伟石先生为公司持续督导工作的保荐 代表人。现为更好地开展后续的持续督导工作，国金证券决定委派保荐代表人崔 敏捷女士和黄世瑾先生（简历详见附件）接替刘源先生和刘伟石先生继续履行公 司持续督导期间的工作。 黄世瑾先生：国金证券股份有限公司上海证券承销保荐分公司保荐 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥1,011,458,568.59, representing a 13.02% increase compared to ¥894,948,098.95 in the same period last year[19]. - Net profit attributable to shareholders was ¥197,661,591.44, a significant increase of 46.54% from ¥134,887,213.05 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥193,733,354.17, up 48.41% from ¥130,543,414.51 year-on-year[19]. - Basic earnings per share increased by 27.17% to ¥0.2818 from ¥0.2216 in the same period last year[19]. - The total profit reached 228.71 million yuan, up 42.65% compared to the same period last year[41]. - The company reported a significant increase in construction in progress, rising to ¥110,832,339.21 from ¥78,057,355.85, an increase of approximately 41.9%[164]. - The company’s total comprehensive income for the first half of 2023 was CNY 107,094,418.16, compared to a loss of CNY 70,048,946.29 in the same period of 2022[172]. - The company reported a total revenue from sales of goods and services of CNY 1,017,734,404.34, up from CNY 846,735,398.62 in the same period last year, marking an increase of approximately 20.2%[177]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,548,700,558.22, a decrease of 2.48% from ¥3,639,117,963.07 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 3.71% to ¥2,603,411,549.83 from ¥2,703,749,664.26 at the end of the previous year[19]. - Total liabilities increased to ¥898,941,209.44 from ¥879,192,754.90, reflecting a rise of about 2.0%[165]. - Current liabilities totaled ¥813,081,074.86, up from ¥754,939,997.44, indicating an increase of approximately 7.6%[165]. - The company's total equity as of June 30, 2023, is 70,138.7335 million, with a registered capital of 70,138.7335 million[197]. Cash Flow - The net cash flow from operating activities was ¥123,191,852.79, down 6.83% from ¥132,222,204.29 in the same period last year[19]. - The company's investment activities generated a net cash flow of -¥92,967,216.55, a significant decrease of 92.85% compared to -¥48,207,873.28 in the same period last year, mainly due to the net redemption of ¥50 million in financial products[51]. - Cash and cash equivalents at the end of the period totaled CNY 945,716,264.17, down from CNY 1,062,579,204.42 at the beginning of the year, reflecting a decrease of approximately 11%[178]. Research and Development - Research and development expenses increased by 34.84% to ¥43,115,918.05, primarily due to investments in the clinical application expansion of Wuling capsules in mental and physical health fields and the development of the indication for IBS-D for Pukapofei tablets[51]. - The R&D expenditure for the first half of 2023 was 600 million yuan, accounting for 8.3% of total revenue[186]. - The company is focusing on research and development of new technologies to drive innovation and growth in the upcoming quarters[190]. Market Position and Strategy - The company is positioned as a leader in the pharmaceutical field of medicinal fungi, focusing on innovation and development[30]. - The company continues to strengthen market expansion, particularly in core products like Wuling Capsules and Lingze Tablets, which have shown good sales growth[41]. - The company plans to enhance its market competitiveness by expanding into new channels such as "Internet+" and e-commerce[84]. - The company is actively exploring new sales channels, including e-commerce platforms like Alibaba Health and JD Medicine, to enhance product accessibility[41]. Risks and Compliance - The company has outlined its commitment to ethical practices in its share issuance and trading activities, enhancing its reputation in the market[106]. - The company faces risks from industry policy changes and will adjust its business strategies accordingly[84]. - The company has recognized significant goodwill from acquisitions, which poses a risk of impairment if future earnings do not meet expectations[86]. Shareholder Information - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, totaling 129,890,463 shares, with 90,000,000 shares pledged[149]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[153]. - The total number of shareholders at the end of the reporting period was 34,061[149]. Community and Environmental Responsibility - The company has been actively involved in community welfare activities, including support for the elderly and donations to disabled individuals[104]. - The company emphasizes environmental protection and has been operating under the ISO 14001 environmental management system for nearly 20 years[104]. - The company focuses on sustainable supply chain development, incorporating social responsibility performance into supplier assessments[103].

证券代码：300181 证券简称：佐力药业 公告编号：2023-035 1、审议通过《关于<公司 2023 年半年度报告及其摘要>的议案》 经审核，监事会认为董事会编制和审核公司《2023 年半年度报告及其摘要》 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司 2023 年半年度经营的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 《2023 年半年度报告》及《2023 年半年度报告摘要》具体内容详见公司同 日披露在中国证监会指定创业板信息披露网站上的相关公告。《2023 年半年度报 告披露提示性公告》将同时刊登在公司指定信息披露报刊证券时报、中国证券报、 上海证券报、证券日报。 浙江佐力药业股份有限公司 第七届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第七届监事会第十五次会 议于2023年8月7日在公司会议室以现场表决的方式召开。会议通知于2023年7 月27日以专人送达、电话、传真及电子邮件等相结合方式送达各监 ...

一、关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项 说明和独立意见 1、报告期内，公司与控股股东及其他关联方的资金往来严格遵守《上市公 司监管指引第8号——上市公司资金往来、对外担保的监管要求》的规定，公司 不存在控股股东及其他关联方占用公司资金的情况，也不存在以前年度发生并延 续至报告期的占用公司资金的情况。 2、报告期内，除《2023年半年度报告》"【第六节、重要事项】十二、重大 合同及其履行情况"中所述的担保事项外，公司不存在其他对外担保情况，不存 在为控股股东、实际控制人及其他关联方、任何非法人单位或个人提供担保的情 况。 浙江佐力药业股份有限公司 独立董事关于第七届董事会第十七次会议 相关事项的独立意见 二、关于2023年半年度募集资金存放与使用情况的独立意见 根据《上市公司独立董事规则》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等有关法律、法规、规范性文件以及《浙江佐力药业股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，我们作为浙江佐力药业股份有限公司（以 下简称"公司"）的独立董事，经审慎分析，现就 ...

`证券代码：300181 证券简称：佐力药业 公告编号：2023-034 浙江佐力药业股份有限公司 第七届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第七届董事会第十七次会 议于 2023 年 8 月 7 日在公司会议室以现场和通讯表决相结合的方式召开。会议 通知于 2023 年 7 月 27 日以专人送达、电话、传真及电子邮件等相结合方式送 达各董事。会议应出席董事 9 人（其中独立董事潘斌先生、朱建先生、王萍先 生以通讯表决方式审议表决），实际出席董事 9 人。会议由公司董事长俞有强先 生主持，公司监事、高管列席会议。会议的召开符合《公司法》、《公司章程》的 规定。 二、董事会会议审议情况 1、审议通过《关于<公司 2023 年半年度报告及其摘要>的议案》 董事会认为：公司《2023 年半年度报告及其摘要》的编制和审核程序符合 相关法律法规，报告内容真实、准确、完整地反映了公司经营的实际情况，不存 在虚假记载、误导性陈述或重大遗漏。《2023 年半年度报告》 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-039 浙江佐力药业股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》的相关规定，现将浙江佐力药业股份有 限公司（以下简称"公司"或"本公司"）2023 年半年度募集资金存放与使用情况 专项说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 本公司经中国证券监督管理委员《关于同意浙江佐力药业股份有限公司向特定 对象发行股票注册的批复》 (证监许可[2022]2064号)同意注册，由主承销商国金 证券股份有限公司通过深圳证券交易所系统采用包销方式，向特定对象发行人民 币普通股(A股)股票9,276.25万股，发行价为每股人民币为9.81元，共计募集资金 总额为人民币91,000.00万元，扣除券商承销佣金及保荐费944 ...

2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：浙江佐力药业股份有限公司 单位：万元 | | 资金占用方 | 占用方与上 | 上市公司核算的 | 2023 | 年期 | 2023 年度占用 | 2023 年度占 | 2023 | 年度偿 | 2023 年期 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 市公司的关 | | 初占用资 | | 累计发生金额 | 用资金的利息 | | 还累计发生 | 末占用资 | | 占用性质 | | | 名称 | | 会计科目 | | | | | | | | 原因 | | | | | 联关系 | | 金余额 | | （不含利息） | （如有） | | 金额 | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | | | | | 小计 | - | - | - | | | | | ...

2023 | 保荐人名称： | 国金证券股份有限公司 | 被保荐公司简称：佐力药业 | | --- | --- | --- | | 保荐代表人姓名：刘源 | | 联系电话：021-68826021 | | 保荐代表人姓名：刘伟石 | | 联系电话：021-68826021 | | 1.公司信息披露审阅情况 | | | --- | --- | | (1) 是否及时审阅公司信息披露文件 | 是 | | 未及时审阅公司信息披露文件的次数 (2) | 0 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | (1) 是否督导公司建立健全规章制度(包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度) | | | (2) 公司是否有效执行相关规章制度 | 已有效执行相关制度 | | 3.募集资金监督情况 | | | (1) 查询公司募集资金专户次数 | 每月查询 | | (2)公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | (1) 列席公司股东大会次数 | 0 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,805,155,365.79, representing a 23.86% increase compared to CNY 1,457,396,066.42 in 2021[17] - The net profit attributable to shareholders for 2022 was CNY 273,006,652.56, a 52.17% increase from CNY 179,408,091.21 in the previous year[17] - The basic earnings per share for 2022 was CNY 0.45, reflecting a 55.17% increase from CNY 0.29 in 2021[17] - The total assets at the end of 2022 amounted to CNY 3,639,117,963.07, a 32.40% increase from CNY 2,748,532,182.07 at the end of 2021[17] - The net cash flow from operating activities for 2022 was CNY 318,591,105.19, up 26.53% from CNY 251,798,511.89 in 2021[17] - The weighted average return on equity for 2022 was 14.32%, an increase from 10.83% in 2021[17] - The net profit after deducting non-recurring gains and losses for 2022 was CNY 264,713,695.17, a 52.94% increase from CNY 173,082,925.27 in 2021[17] - The company reported a quarterly revenue of CNY 460,752,763.66 in Q4 2022, with a net profit of CNY 69,046,607.34 attributable to shareholders[19] - The total profit for the year was CNY 324.12 million, an increase of 45.80% compared to the previous year[46] - The net profit attributable to shareholders reached CNY 273.01 million, marking a growth of 52.17% year-on-year[46] Market Position and Growth - The Chinese traditional medicine market is projected to grow to approximately 481.8 billion CNY by 2023, up from 430.2 billion CNY in 2021, indicating a robust market expansion[29] - The company is positioned in the pharmaceutical manufacturing industry, specifically in traditional Chinese medicine, which is supported by favorable government policies aimed at promoting its development[27] - The company anticipates that the market for traditional Chinese medicine will continue to grow due to increasing healthcare awareness and an aging population[28] - The company ranked 56th in the "2021 Top 100 Chinese Traditional Medicine Enterprises" list by Minai Network and 35th in the "2022 Comprehensive Competitiveness of Chinese Traditional Medicine Enterprises" list[30] - The company aims to develop the Wuling series into a 2 billion RMB product, the Bailing tablets into a 1 billion RMB product, and the traditional Chinese medicine pieces and formula granules into a 1 billion RMB scale product[99] Product Development and Innovation - The core product, Wuling Capsule, achieved a market share of 11.88% in 2021, ranking 1st in the urban public hospital market for neurological disease medications[31] - Wuling Capsule maintained a market share of 8.27% in county-level public hospitals, ranking 1st in 2021 for neurological disease medications[31] - The company’s Wuling Capsule was ranked 2nd in the category of traditional Chinese medicine for headache and insomnia, and Bailing Tablets ranked 6th in the tonics category in 2022[30] - The company’s product portfolio includes Wuling series, Bailing Tablets, Lingze Tablets, and Linglianhua Granules, focusing on traditional Chinese medicine and innovative formulations[33] - Lingze Tablets and Linglianhua Granules are newly developed products based on Wuling fungus powder, targeting specific health conditions[35] - The company has been awarded the title of "Most Growth Potential Enterprise" in the Chinese pharmaceutical industry for 2022[30] - The company has launched the first generic drug of Pugongying Calcium Tablets in China, which is now included in the National Drug Administration's Chemical Drug Directory, targeting the constipation caused by irritable bowel syndrome[36] Research and Development - The company plans to raise CNY 910 million through refinancing to support product R&D and industrialization, including projects for smart traditional Chinese medicine production and digital operation systems[46] - The company has completed the provincial and national standard filing for 251 types of traditional Chinese medicine formula granules, actively promoting the standardization of TCM products amid the transition to new industry standards[37] - The company has made significant progress in the research and development of Wuling capsules for Alzheimer's treatment, currently in the preclinical research phase[49] - The company’s R&D investment amounted to 65,356,875.08 yuan in 2022, representing a significant increase from previous years[64] - The company's R&D investment accounted for 3.62% of operating revenue in 2022, up from 3.13% in 2021[65] Financial Management and Governance - The company has not reported any significant discrepancies between financial data under international and Chinese accounting standards, ensuring consistency in financial reporting[21] - The company has established a comprehensive internal control system to enhance governance and ensure the achievement of operational goals[112] - The company has not experienced any significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[112] - The company has maintained complete independence from its controlling shareholders in terms of business, personnel, assets, and financial management[113] - The company has a structured remuneration management system for directors and senior management, which is reviewed and approved by the board and shareholders[130] Risk Management and Future Outlook - The company has acknowledged potential risks related to industry policy changes and drug research and development in its future outlook[3] - The company recognizes the high risks associated with drug research and development and plans to optimize its innovation mechanisms and project selection[103] - The company plans to enhance its digital marketing strategies to improve customer acquisition and retention rates[106] - The management provided guidance for the upcoming fiscal year, projecting a revenue growth rate of approximately 15%[106] - The company plans to strengthen its risk management mechanisms in response to industry policy changes and enhance its marketing strategies to adapt to market dynamics[102] Employee and Corporate Social Responsibility - The total number of employees at the end of the reporting period is 2,455, with 1,839 in the parent company and 616 in major subsidiaries[140] - The company has implemented a flexible salary system, including annual salary, middle management position salary system, and employee position salary system[141] - The company provides various benefits such as free lunch, holiday gifts, and health check-ups, ensuring compliance with national and local laws regarding employee welfare[141] - The company has established a comprehensive training plan based on the 2022 operational plan, focusing on employee development and departmental training needs[142] - The company has disclosed its 2022 Social Responsibility Report and ESG report on April 26, 2023[155] Shareholder Engagement and Communication - The company conducted multiple investor communication activities, including a performance briefing on May 10, 2022, where investor inquiries were addressed[105] - The company held two shareholder meetings in 2022, with participation rates of 28.03% for the first extraordinary meeting and 30.94% for the annual meeting[116] - The company actively engages with investors through various channels, enhancing transparency and protecting minority shareholders' rights[111] Capital Structure and Share Issuance - The company plans to raise a total of 910 million yuan through a private placement of 92,762,487 shares at a price of 9.81 yuan per share[190] - The issuance of shares is part of the company's strategy to raise capital for future growth initiatives[196] - The total number of restricted shares at the end of the period is 92,762,487, all of which are related to the issuance of shares to specific targets[200] - The company has received approval from the China Securities Regulatory Commission for the stock issuance, indicating regulatory compliance[196]